Retatrutide is in Phase 3 trials for chronic weight management with weight-loss numbers that exceed both tirzepatide and semaglutide in head-to-head Phase 2 work. The mechanism is a triple agonist: GIP, GLP-1, and glucagon receptor. The glucagon component is new in the weight-loss class and produces a different cardiometabolic response than the GIP/GLP-1 dual agonism of tirzepatide. The compound is not FDA-approved as of mid-2026; trial participants and users sourcing compounded retatrutide off-label both have tracking requirements that differ from the approved GLP-1s. This guide is the operational tracker setup for retatrutide specifically.
What retatrutide is and what it is not
Retatrutide is an investigational triple receptor agonist developed by Eli Lilly. It binds the GIP receptor, the GLP-1 receptor, and the glucagon receptor simultaneously. The glucagon component is the distinctive feature - glucagon receptor activation produces a thermogenic effect that contributes additional weight loss beyond what appetite suppression alone delivers in pure GLP-1s.
Phase 2 trial data published in NEJM reported mean weight loss of approximately 24% at 48 weeks at the highest dose. Phase 3 trials (TRIUMPH program) are ongoing. The compound is expected to file for FDA approval in late 2026 or 2027 based on current trial timelines, but timing depends on trial completion and FDA review. As of mid-2026, retatrutide is not an approved medication and is not legally available outside of clinical trials and compounded sources.
For practical tracking purposes, this means two distinct populations exist: trial participants (who have monitoring built into the protocol) and off-label users on compounded retatrutide (who do not). Both groups benefit from structured tracking; the off-label group benefits more because the safety monitoring built into trials is not in place.
What is different about a triple agonist for tracking
Three tracking differences worth knowing for retatrutide specifically.
Cardiometabolic signal. Glucagon receptor activation produces an increase in resting heart rate that is more pronounced than what occurs with GLP-1 monoagonism. Phase 2 data showed average resting heart rate increases of 5-10 bpm depending on dose. Tracking resting heart rate daily (most wearables capture this automatically) and flagging trends is part of the protocol.
The glucagon component also produces a modest increase in hepatic glucose output - usually offset by the GIP/GLP-1 components but worth tracking via quarterly fasting glucose and HbA1c. For most users this is neutral; for some it produces a different pattern than tirzepatide.
GI signature. Phase 2 data showed GI side effects (nausea, diarrhea, constipation) at incidence rates similar to tirzepatide but with slightly tighter clustering in the early titration weeks. Daily GI logging in week 1-4 of each new step is worth more attention than at the analogous point on tirzepatide.
Energy and thermogenic response. The glucagon component produces a thermogenic effect - some users report a ‘running warm’ subjective experience and slightly elevated basal energy expenditure. Worth noting in the daily log; not a side effect per se, but a different pattern than tirzepatide.
The daily and weekly log structure for retatrutide
The daily check on retatrutide adds two dimensions to the standard GLP-1 rubric.
- Nausea (1-5). Standard.
- Fatigue (1-5). Standard.
- GI changes (free text + 1-5). More attention than tirzepatide; week 1-4 of each step.
- Hydration (oz). Standard; possibly higher target on retatrutide due to thermogenic component.
- Protein (grams). Standard; muscle preservation is the same priority.
- Resting heart rate (bpm). Pulled from wearable; daily morning value.
- Subjective ‘running warm’ (1-5). Thermogenic-component indicator; useful for tracking glucagon-component intensity.
The weekly summary maps the daily log to the injection day and includes a heart-rate trend explicitly. A representative summary at week 4 of a new step might read: ‘Day-1 nausea averaged 2.5, day-2-3 GI changes mild. Resting HR averaged 68 bpm this week vs 62 baseline pre-protocol; trend is up 6 bpm cumulative. Protein hit on six of seven days. Smoothed weight down 1.6 lbs week-over-week. Next labs in 6 weeks.’ The HR trend is the operative new data versus tirzepatide tracking.
Quarterly labs: what to add on retatrutide
Quarterly bloodwork on retatrutide should include the standard GLP-1 panel plus three additions worth flagging because of the glucagon component.
Standard panel: CBC, CMP, lipid panel, HbA1c, fasting insulin, fasting glucose, hsCRP, TSH, free T4. These are the baseline metrics for any weight-loss protocol.
Retatrutide-specific additions:
- Comprehensive metabolic panel with fractionated bilirubin. Liver enzyme trends are worth watching closely on glucagon-receptor-active compounds.
- Fasting glucose AND fasting insulin together. HOMA-IR calculation; the glucagon component has implications for insulin sensitivity that the standard A1c alone may not capture.
- Resting ECG or cardiac history check at baseline. Particularly for users with any cardiac history; the resting HR increase is mild for most but worth a baseline.
Quarterly trends across these panels become the lab integration in miora. Drop the PDF in the iMessage thread and miora parses the values, charts the trend, and flags shifts.
Trial participation versus off-label compounded use
The two populations using retatrutide in 2026 have meaningfully different risk profiles.
Trial participants. The trial protocol includes structured monitoring: visits at defined intervals, labs at defined intervals, adverse event reporting, dose-adjustment protocols managed by the investigator. The trial sponsor monitors for safety signals across the population. The compound is sourced and quality-controlled by the trial. Tracking in miora complements the trial monitoring; the daily six-dimension log fills the gap between scheduled visits.
Off-label compounded users. Different situation. The compound is sourced from a 503A compounding pharmacy (and the regulatory environment around this is the subject of the July 2026 PCAC vote). There is no investigator monitoring; the user and their prescriber are the safety system. Tracking matters more because the structured oversight is not in place.
miora does not source retatrutide, recommend specific compounders, or suggest doses. For off-label users, the prescriber conversation is non-optional - this is not a substance to run without clinical oversight, particularly given the limited long-term real-world safety data.
When to flag the retatrutide trend
Thresholds worth bringing to a clinician (or trial investigator) for retatrutide specifically:
- Resting heart rate up more than 10 bpm from pre-protocol baseline. Glucagon-component response; worth labs and possibly dose evaluation.
- New or worsening cardiac symptoms. Chest discomfort, palpitations, exercise intolerance. Stop self-management; this is a clinician call immediately.
- Liver enzymes trending up across two panels. AST or ALT rising; worth investigation.
- Fasting glucose trending up on quarterly panel. Possible glucagon-related insulin-resistance signal.
- Smoothed weight loss faster than 3% per month. Aggressive rate; body composition check warranted.
- Protein intake below 80 g for two weeks. Muscle-preservation risk; magnified on retatrutide because the thermogenic effect adds to the calorie deficit.
The cardiometabolic flags are the ones most worth taking seriously and most worth catching early.
What miora does for retatrutide tracking
The daily flow is one evening text including the standard dimensions plus the retatrutide-specific additions. Example: ‘reta check, day 2: nausea 2 / fatigue 2 / GI mild / 64 oz / 105 g / HR 67 / running warm 3.’ miora parses the dimensions and logs them.
The morning text from miora the next day might include the morning resting HR pull from your wearable, the prior day’s protein and hydration relative to target, and a quick scan of the injection-day curve relative to last cycle. The weekly summary surfaces the HR trend, the GI cluster, and the cardiometabolic signals separately from the weight trend.
For lab integration, drop the quarterly panel PDF into the thread and miora parses values, charts trends, and flags items that crossed reference ranges or trended meaningfully since the last panel. The clinician-ready summary on demand includes the retatrutide-specific HR, liver enzyme, and glucose trends explicitly.
What this guide does not do
Three boundaries.
This guide does not recommend retatrutide for any specific person. The compound is not FDA-approved. Trial participation is one access path; off-label compounded use is the other and carries a distinct risk profile. The decision to participate in a trial or to source compounded retatrutide is a clinician conversation, not a community decision.
This guide does not recommend specific compounding pharmacies or sourcing strategies. miora does not source any peptide or compound. References to compounded use are descriptive of what exists in the community, not endorsement.
The guide does not promise that the trial-reported weight-loss numbers will apply to any individual. Phase 2 data are population averages; individual response varies widely and long-term outcomes are still being studied. This content is for informational purposes only and is not medical advice. Retatrutide is an investigational compound. Off-label use requires clinician supervision and carries risks not yet fully characterized in long-term real-world data.
